CoChat
Sign Up
Cited by 109Cancer, Hypoxia, and MetabolismMetabolism, Diabetes, and CancerKruppel-like factors research

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1α and HIF-2α target genes

Open access
Chun, Sang Y, Johnson, Craig, Washburn, Joseph G, Cruz-Correa, Marcia R, Dang, Duyen T, Dang, Long H·2010·Molecular Cancer
DOI 10.1186/1476-4598-9-293PMC PMC2999617
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: Activating KRAS mutations are important for cancer initiation and progression; and have recently been shown to cause primary resistance to therapies targeting the epidermal growth factor receptor. Therefore, strategies are currently in development to overcome treatment resistance due to oncogenic KRAS. The hypoxia-inducible factors-1α and -2α (HIF-1α and HIF-2α) are activated in cancer due to dysregulated ras signaling. Methods: To understand the individual and combined roles of HIF-1α and HIF-2α in cancer metabolism and oncogenic KRAS signaling, we used targeted homologous recombination to disrupt the oncogenic KRAS, HIF-1α, and HIF-2α gene loci in HCT116 colon cancer cells to generate isogenic HCT116 WT KRAS, HCT116 HIF-1α-/-, HCT116 HIF-2α-/-, and HCT116 HIF-1α-/-HIF-2α-/- cell lines. Results: Global gene expression analyses of these cell lines reveal that HIF-1α and HIF-2α work together to modulate cancer metabolism and regulate genes signature overlapping with oncogenic KRAS. Cancer cells with disruption of both HIF-1α and HIF-2α or oncogenic KRAS showed decreased aerobic respiration and ATP production, with increased ROS generation. Conclusion: Our findings suggest novel strategies for treating tumors with oncogenic KRAS mutations.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/1476-4598-9-293

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Analyses of genes regulated by oncogenic KRAS, HIF-1α, HIF-2α, and both HIF-1α and HIF-2α. Expression of target genes in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cell lines. HK2, hexokinase 2; LDHA, lactate dehydrogenase A; MGLL, monoglyceride lipase; ANGPTL4, angiopoietin-like protein 4; and VEGFA, vascular endothelial growth factor A relative to β-actin were measured by real-time reverse transcription-PCR (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. c, clone.
Figure 1 Analyses of genes regulated by oncogenic KRAS, HIF-1α, HIF-2α, and both HIF-1α and HIF-2α. Expression of target genes in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cell lines. HK2, hexokinase 2; LDHA, lactate dehydrogenase A; MGLL, monoglyceride lipase; ANGPTL4, angiopoietin-like protein 4; and VEGFA, vascular endothelial growth factor A relative to β-actin were measured by real-time reverse transcription-PCR (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. c, clone.CC BY · PubMed Central
Figure 2 Analyses of metabolism gene set regulated by oncogenic KRAS and HIF. A, heatmap analysis comparing the following metabolism gene sets: HCT116 vs HCT116HIF-1α-/-, HCT116 vs HCT116HIF-2α-/-, HCT116 vs HCT116HIF-1α-/-HIF-2α-/-, and HCT116 vs HCT116WT KRAS cells. Expression values are averages of three samples. B, Venn diagrams analyzing the extent of overlap of the following metabolism gene sets: 1) HCT116 vs HCT116HIF-1α-/-, HCT116 vs HCT116HIF-2α-/-, and HCT116 vs HCT116HIF-1α-/-HIF-2α-/-; 2) HCT116 vs HCT116HIF-1α-/-HIF-2α-/- and HCT116 vs HCT116WT KRAS. Each circle represents a single gene set; and the number of genes common between the gene sets is denoted within the overlaps of the circles. C, Clonogenic survival assay of HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cells. c, clone.
Figure 2 Analyses of metabolism gene set regulated by oncogenic KRAS and HIF. A, heatmap analysis comparing the following metabolism gene sets: HCT116 vs HCT116HIF-1α-/-, HCT116 vs HCT116HIF-2α-/-, HCT116 vs HCT116HIF-1α-/-HIF-2α-/-, and HCT116 vs HCT116WT KRAS cells. Expression values are averages of three samples. B, Venn diagrams analyzing the extent of overlap of the following metabolism gene sets: 1) HCT116 vs HCT116HIF-1α-/-, HCT116 vs HCT116HIF-2α-/-, and HCT116 vs HCT116HIF-1α-/-HIF-2α-/-; 2) HCT116 vs HCT116HIF-1α-/-HIF-2α-/- and HCT116 vs HCT116WT KRAS. Each circle represents a single gene set; and the number of genes common between the gene sets is denoted within the overlaps of the circles. C, Clonogenic survival assay of HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cells. c, clone.CC BY · PubMed Central
Figure 3 Analyses of target genes regulating phospholipids synthesis. A, overview of mitochondrial respiration and the contributory role of mitochondrial phospholipids synthesis. B, expression of genes regulating phospholipids synthesis in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cell lines. c, clone. ACSL5, acyl-CoA synthetase 5; AGPAT7, 1-acyl-sn-glycerol-3-phosphate acyltransferase 7; and PCK2, phosphoenolpyruvate carboxykinase 2 relative to β-actin were measured by real-time reverse transcription-PCR (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. C, Expression of ACSL5, AGPAT7, and PCK2 in primary colon cancers. Gene expression, relative to β-ACTIN, in normal mucosa and primary tumor was determined by real-time RT-PCR. Log expression values were graphed as box and whiskers plots; showing median expression (horizontal line), surrounded by the first and third quartiles of those values (box), and the extreme values (whiskers). Hypothesis testing was performed using the Wilcoxon signed-rank test, with * = p < 0.05 considered statistically significant, comparing tumor to mucosa. D, western blot of ACSL5 in cell lines, with antibody to α-tubulin as loading control. c, clone. E, ACSL5 promoter activity in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, and HCT116HIF-1α-/-HIF-2α-/- cells (n = 5). Diamond represents HRE site. The pGL3pro construct is a minimal promoter Firefly luciferase reporter. The ACSL5-pGL3pro construct contains an 1883 bp fragment of the 5' untranslated region of the ACSL5 gene with the HRE site. This construct is subjected to site-directed mutagenesis at the HRE site to generate the ACSL5(-HRE)-pGL3pro. Bars, stdev. p < 0.05 by Student's t test comparing transfection with pGL3pro construct versus ACSL5-pGL3pro or ACSL5(-HRE)-pGL3pro constructs.
Figure 3 Analyses of target genes regulating phospholipids synthesis. A, overview of mitochondrial respiration and the contributory role of mitochondrial phospholipids synthesis. B, expression of genes regulating phospholipids synthesis in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cell lines. c, clone. ACSL5, acyl-CoA synthetase 5; AGPAT7, 1-acyl-sn-glycerol-3-phosphate acyltransferase 7; and PCK2, phosphoenolpyruvate carboxykinase 2 relative to β-actin were measured by real-time reverse transcription-PCR (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. C, Expression of ACSL5, AGPAT7, and PCK2 in primary colon cancers. Gene expression, relative to β-ACTIN, in normal mucosa and primary tumor was determined by real-time RT-PCR. Log expression values were graphed as box and whiskers plots; showing median expression (horizontal line), surrounded by the first and third quartiles of those values (box), and the extreme values (whiskers). Hypothesis testing was performed using the Wilcoxon signed-rank test, with * = p < 0.05 considered statistically significant, comparing tumor to mucosa. D, western blot of ACSL5 in cell lines, with antibody to α-tubulin as loading control. c, clone. E, ACSL5 promoter activity in HCT116, HCT116HIF-1α-/-, HCT116HIF-2α-/-, and HCT116HIF-1α-/-HIF-2α-/- cells (n = 5). Diamond represents HRE site. The pGL3pro construct is a minimal promoter Firefly luciferase reporter. The ACSL5-pGL3pro construct contains an 1883 bp fragment of the 5' untranslated region of the ACSL5 gene with the HRE site. This construct is subjected to site-directed mutagenesis at the HRE site to generate the ACSL5(-HRE)-pGL3pro. Bars, stdev. p < 0.05 by Student's t test comparing transfection with pGL3pro construct versus ACSL5-pGL3pro or ACSL5(-HRE)-pGL3pro constructs.CC BY · PubMed Central
Figure 4 Quantitation of total cellular (A) phosphatidyl choline (PC) and (B) cardiolipin (CL) levels in HCT116, HCT116HIF-1α-/-HIF-2α-/-, HCT116WT KRAS cells, HCT116 cells transduced with control scramble shRNA, and HCT116 cells transduced with ACSL5 shRNA (n = 3). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells or shRNA transduced cells with parental HCT116 cells. Four lentiviral constructs carrying ACSL5 shRNA were tested for effectiveness in suppressing ACSL5 expression in comparison to the lentiviral construct carrying control scramble shRNA (Additional file 3, Fig. S3). Clone H45551 was chosen for subsequent experiments as it was the most effective (Additional file 3, Fig. S3).
Figure 4 Quantitation of total cellular (A) phosphatidyl choline (PC) and (B) cardiolipin (CL) levels in HCT116, HCT116HIF-1α-/-HIF-2α-/-, HCT116WT KRAS cells, HCT116 cells transduced with control scramble shRNA, and HCT116 cells transduced with ACSL5 shRNA (n = 3). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells or shRNA transduced cells with parental HCT116 cells. Four lentiviral constructs carrying ACSL5 shRNA were tested for effectiveness in suppressing ACSL5 expression in comparison to the lentiviral construct carrying control scramble shRNA (Additional file 3, Fig. S3). Clone H45551 was chosen for subsequent experiments as it was the most effective (Additional file 3, Fig. S3).CC BY · PubMed Central
Figure 5 Effects of genetic inactivation of oncogenic KRAS or both HIF-1α and HIF-2α on mitochondrial metabolism. A, change in cellular O2 consumption; B, change in MTT reduction; and C, change in intracellular ATP level in HCT116HIF-1α-/-HIF-2α-/- and HCT116WT KRAS relative to HCT116 cells (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. D, cellular and mitochondrial ROS levels in HCT116, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cells, as measured by the fluorescent dyes CM-H2DCFDA and MitoSOX.
Figure 5 Effects of genetic inactivation of oncogenic KRAS or both HIF-1α and HIF-2α on mitochondrial metabolism. A, change in cellular O2 consumption; B, change in MTT reduction; and C, change in intracellular ATP level in HCT116HIF-1α-/-HIF-2α-/- and HCT116WT KRAS relative to HCT116 cells (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing knockout cells with parental HCT116 cells. D, cellular and mitochondrial ROS levels in HCT116, HCT116HIF-1α-/-HIF-2α-/-, and HCT116WT KRAS cells, as measured by the fluorescent dyes CM-H2DCFDA and MitoSOX.CC BY · PubMed Central
Figure 6 Effects of ACSL5 gene knockdown on mitochondrial metabolism and tumorigenesis. A, change in cellular O2 consumption; and B, change in intracellular ATP level in HCT116 and LOVO cells transduced with ACSL5 shRNA relative to control scramble shRNA (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing cells transduced with ACSL5 shRNA versus control scramble shRNA. C, cellular and mitochondrial ROS levels in HCT116 cells transduced with ACSL5 shRNA versus control scramble shRNA, as measured by the fluorescent dyes CM-H2DCFDA and MitoSOX.
Figure 6 Effects of ACSL5 gene knockdown on mitochondrial metabolism and tumorigenesis. A, change in cellular O2 consumption; and B, change in intracellular ATP level in HCT116 and LOVO cells transduced with ACSL5 shRNA relative to control scramble shRNA (n = 5). Bars, stdev. p < 0.05 by Student's t test comparing cells transduced with ACSL5 shRNA versus control scramble shRNA. C, cellular and mitochondrial ROS levels in HCT116 cells transduced with ACSL5 shRNA versus control scramble shRNA, as measured by the fluorescent dyes CM-H2DCFDA and MitoSOX.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 39 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Chun, S. Y., Johnson, C., Washburn, J. G., Cruz-Correa, M. R., Dang, D. T., & Dang, L. H.
Affiliations
  • University of Michigan (US)
  • University of Puerto Rico System (PR)
  • University of Florida (US)
Corresponding author
Dang, Long H
ORCID
Venue
Molecular Cancer
Publisher
Springer Science and Business Media LLC
Published
2010-11-13
Volume
9
Issue
1
Pages
293-293
ISSN
1476-4598 (ISSN-L)
DOI
10.1186/1476-4598-9-293
PMC
PMC2999617
OpenAlex
W2107951449
Cited by
109
References
39
Citations by year
2026: 2 · 2025: 6 · 2024: 8 · 2023: 6 · 2022: 14 · 2021: 12 · 2020: 8 · 2019: 4 · 2018: 3 · 2017: 3 · 2016: 6 · 2015: 4 · 2014: 13 · 2013: 8 · 2012: 3
FWCI
2.01
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Molecular Cancer (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Deep Blue (University of Michigan) (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Pfizer
  • National Comprehensive Cancer Network
  • National Institutes of Health
  • University of Michigan Comprehensive Cancer Center
  • National Cancer Institute (R21CA115809, K22CA111897)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Kruppel-like factors research
Keywords
oncogenic KRAS, HIF-1α, HIF-2α, hypoxia-inducible factor, colon cancer, mitochondrial metabolism, aerobic respiration, reactive oxygen species, ATP production, KRAS mutation, isogenic cell lines, HCT116 cells, cancer metabolism
MeSH terms
Endothelial PAS Domain-Containing Protein 1, Adenosine Triphosphate, Colonic Neoplasms, Humans, Mitochondria, Oxygen Consumption, Proto-Oncogene Proteins, Blotting, Western, Proto-Oncogene Proteins p21(ras), Mutagenesis, Site-Directed, Reactive Oxygen Species, ras Proteins, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, HCT116 Cells, Cell Line, Tumor, Basic Helix-Loop-Helix Proteins, Hypoxia-Inducible Factor 1, alpha Subunit

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review